Eye on the prize: $15.9m boost for Opthea’s vision impairment therapy
Opthea (ASX:OPT), a clinical-stage biopharmaceutical company based in Melbourne, has announced a boost to its cash reserves, receiving a $15.9m research and development (R&D) tax incentive from the Australian Taxation Office. The funding supports Opthea’s development of sozinibercept, an innovative therapy targeting wet age-related macular degeneration (wet AMD), one of the leading causes of severe […]
Eye on the prize: $15.9m boost for Opthea’s vision impairment therapy Read More »